Cart is empty 
Liraglutide (GLP1) 10mg
In stock
Order today and your order ships in:
Liraglutide is a derivative of GLP-1, a naturally occurring peptide known to lower blood sugar levels and enhance insulin secretion. Research shows that Liraglutide (GLP-1 Analogue) may also improve heart, liver, and lung function while helping to slow or prevent the effects of Alzheimer’s disease.
Liraglutide has been shown to significantly decrease appetite by delaying gastric emptying and reducing intestinal motility. Liraglutide has been modified to have a longer half-life and more favorable pharmacokinetics.
Where to buy Liraglutide 10mg? Shop now for Liraglutide 10mg with exceptional quality and get more for less with our bulk sales. Quick 48-hour delivery available.
-
- Purity Testing: Determines the level of impurities or contaminants in the product, ensuring it meets research-grade standards.
- Assay Testing: Confirms the compound’s chemical composition and potency, verifying its suitability for experimental use.
-
- High-Performance Liquid Chromatography (HPLC): Analyzes purity by separating and quantifying individual components in the compound.
- Mass Spectrometry (MS): Identifies the molecular structure and verifies the compound’s identity.
- Fourier Transform Infrared Spectroscopy (FTIR): Confirms the compound’s chemical bonds and functional groups.
- Nuclear Magnetic Resonance (NMR): Provides detailed structural analysis of the compound.
- Sterile Water for Injection:
Preferred for single-use applications, sterile water ensures purity and minimizes contamination risks. It’s commonly used in studies requiring a single administration. - Bacteriostatic Water (BAC Water):
Containing 0.9% benzyl alcohol, BAC water helps prevent bacterial growth, making it ideal for studies requiring multiple administrations over several days or weeks. Researchers value its stability for extended research. BAC water is included as a gift with any peptide vial purchase.
Properties
Liraglutide (GLP1) 10mg
Chemical Formula: C172H265N43O51
Molecular Mass: 3751.24
Synonyms: Liraglutide, NN2211, Liraglultidum, Liraglutidea
PubChem: 16134956
CAS: 204656-20-2
Total Amount of the Active Ingredient: 10mg (1 vial)
Shelf Life: 36 months
Uncompromising Quality Assurance for Liraglutide
At Triggered Brand, we are dedicated to providing researchers with high-purity Liraglutide that meets the strictest quality standards. Products listed on our site undergo a rigorous quality control process to ensure reliability and consistency for your research.
1. Receipt and Inspection: Upon receiving Liraglutide from our trusted supplier network, we perform a preliminary quality check to ensure the product meets baseline specifications.
2. Purity and Assay Testing: Before products are listed for sale, they undergo third-party purity testing to confirm the percentage of the active compound and assay testing to verify the compound’s concentration.
3. Testing Methods: Our testing partners use advanced analytical techniques, including:
4. Approval for Sale: After these tests return positive results we list Liraglutide 10mg on our site for purchase. This ensures you receive validated research-grade products that you can trust for your experiments. Lab tests are occasionally published on the website.
Scientific literature
From the Incretin Concept and the Discovery of GLP-1 to Today’s Diabetes Therapy
Abstract
Researchers have been looking for insulin-stimulating factors for more than 100 years, and in the 1960ties it was definitively proven that the gastrointestinal tract releases important insulinotropic factors upon oral glucose intake, so-called incretin hormones. The first significant factor identified was the duodenal glucose-dependent insulinotropic polypeptide, GIP, which however, turned out not to stimulate insulin secretion in patients with type 2 diabetes. But resection experiments clearly indicated the presence of an additional incretin, and in 1986, an unexpected processing fragment of the recently identified glucagon precursor, proglucagon, namely truncated glucagon-like peptide 1 (GLP-1 7-36 amide), was isolated from the gut and found to both stimulate insulin secretion and inhibit glucagon secretion. The peptide also inhibited appetite and food intake. Unlike GIP, this peptide had preserved effects in patients with type 2 diabetes and it was soon documented to have powerful antidiabetic effects in clinical studies. Its utility was limited, however, because of an extremely short half-life in humans, but this problem had two solutions, both of which gave rise to important antidiabetic drugs: (1) orally active inhibitors of the enzyme dipeptidylpeptidase 4 (DPP-4 inhibitors), which was responsible for the rapid degradation; the inhibitors protect endogenous GLP-1 from degradation and thereby unfold its antidiabetic activity, and (2) long-acting injectable analogs of GLP-1 protected against DPP-4 degradation. Particularly, the latter, the GLP-1 receptor agonists, either alone or in various combinations, are so powerful that treatment allows more than 2/3 of type 2 diabetes patients to reach glycemic targets. In addition, these agents cause a weight loss which, with the most successful compounds, may exceed 10% of body weight. Most recently they have also been shown to be renoprotective and reduce cardiovascular risk and mortality.
Abstract
Angiotensin II (Ang II), a peptide hormone generated as part of the renin-angiotensin system, has been implicated in the pathophysiology of many cardiovascular diseases such as peripheral artery disease, heart failure, hypertension, coronary artery disease and other conditions. Liraglutide, known as an incretin mimetic, is one of the glucagon-like peptide-1 (GLP-1) receptor agonists, and has been proven to be effective in the treatment of cardiovascular disorders beyond adequate glycemic control. The objective of this review is to compile our recent experimental outcomes-based studies, and provide an overview the cardiovascular protection from liraglutide against Ang II- and pressure overload-mediated deleterious effects on the heart. In particular, the mechanisms of action underlying the inhibition of oxidative stress, vascular endothelial dysfunction, hypertension, cardiac fibrosis, left ventricular hypertrophy and heart failure with liraglutide are addressed. Thus, we support the notion that liraglutide continues to be a useful add-on therapy for the management of cardiovascular diseases.
A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity
Abstract
Background: Obesity is a chronic disease with limited treatment options in pediatric patients. Liraglutide may be useful for weight management in adolescents with obesity.
Methods: In this randomized, double-blind trial, which consisted of a 56-week treatment period and a 26-week follow-up period, we enrolled adolescents (12 to <18 years of age) with obesity and a poor response to lifestyle therapy alone. Participants were randomly assigned (1:1) to receive either liraglutide (3.0 mg) or placebo subcutaneously once daily, in addition to lifestyle therapy. The primary end point was the change from baseline in the body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) standard-deviation score at week 56.
Results: A total of 125 participants were assigned to the liraglutide group and 126 to the placebo group. Liraglutide was superior to placebo with regard to the change from baseline in the BMI standard-deviation score at week 56 (estimated difference, -0.22; 95% confidence interval [CI], -0.37 to -0.08; P = 0.002). A reduction in BMI of at least 5% was observed in 51 of 113 participants in the liraglutide group and in 20 of 105 participants in the placebo group (estimated percentage, 43.3% vs. 18.7%), and a reduction in BMI of at least 10% was observed in 33 and 9, respectively (estimated percentage, 26.1% vs. 8.1%). A greater reduction was observed with liraglutide than with placebo for BMI (estimated difference, -4.64 percentage points) and for body weight (estimated difference, -4.50 kg [for absolute change] and -5.01 percentage points [for relative change]). After discontinuation, a greater increase in the BMI standard-deviation score was observed with liraglutide than with placebo (estimated difference, 0.15; 95% CI, 0.07 to 0.23). More participants in the liraglutide group than in the placebo group had gastrointestinal adverse events (81 of 125 [64.8%] vs. 46 of 126 [36.5%]) and adverse events that led to discontinuation of the trial treatment (13 [10.4%] vs. 0). Few participants in either group had serious adverse events (3 [2.4%] vs. 5 [4.0%]). One suicide, which occurred in the liraglutide group, was assessed by the investigator as unlikely to be related to the trial treatment.
Conclusions: In adolescents with obesity, the use of liraglutide (3.0 mg) plus lifestyle therapy led to a significantly greater reduction in the BMI standard-deviation score than placebo plus lifestyle therapy. (Funded by Novo Nordisk; NN8022-4180 ClinicalTrials.gov number, NCT02918279.).
Liraglutide: Dosing and Mixing for Research
Understanding the Format: Vial
Liraglutide is available in a single vials 10mg these are designed for flexibility in research studies requiring precise preparation and mixing. These formats allow researchers to control mixing solutions and customize protocols according to their study needs.
Mixing Liraglutide Vials
Proper preparation ensures research accuracy and consistency. Researchers typically use one of the following solutions for mixing:
Understanding Dosing for Liraglutide
When conducting research with Liraglutide 10mg Peptide Vials, it is crucial to recognize that dosing parameters vary based on the specific objectives and design of each research study. Research compounds, including Liraglutide GLP1, are intended strictly for in vitro testing and laboratory experimentation purposes and are not approved for human consumption.
In accordance with legal and regulatory guidelines, we cannot provide dosing guidance or recommendations for Liraglutide 10mg Peptide Vial. Providing such advice would violate compliance laws, as it could be interpreted as prescribing usage for research studies.
This product is not a drug, food, or cosmetic and must not be introduced into humans or animals under any circumstances. It should only be handled by licensed, qualified professionals in a controlled research environment.
For information regarding dosing, researchers are encouraged to consult peer-reviewed studies or other reputable scientific sources relevant to their field of study.
Shipping
USA
Canada
If your shipment was seized (International Orders), we will provide a 50% discount applicable on your next purchase. Please contact us for more information.
Disclaimer
The information provided above is not intended to substitute medical advice, diagnosis, or treatment. Should you have any questions regarding a medical condition, seek the advice of your physician or a qualified healthcare provider. In no case should medical advice be disregarded or delayed because of what you have read or seen. We bear no responsibility or liability for your use of any of our research compounds and products. Please note that they are being sold for research purposes ONLY. We do NOT condone any personal use.
Note: In some cases wherein the assigned top colors are out of stock, a different top color will be used to ensure that your order will not be delayed. Should you need assistance identifying the peptide vial that you received, please send us an email at [email protected].
ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.
The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: “in glass”) are performed outside the body. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat and/or cure any medical condition, ailment or disease. Bodily introduction of any kind into animals or human is strictly prohibited by law.
This is the extra content added to the product description.
| How Many Vials? | 1 Vial, 2 Vials, 3 Vials, 4 Vials, 5 Vials, 10 Vials, 20 Vials, 40 Vials, 100 Vials |
|---|
FAQ
Liraglutide (GLP1) 10mg Vials
How to reconstitute Liraglutide (GLP1) 10mg vials?
Liraglutide (GLP1) 10mg vials contain a peptide powder, which is typically a puck or loose bits due to shipping. To reconstitute a Liraglutide (GLP1) 10mg vials, researchers typically use bacteriostatic water, combining it with the peptide powder according to the specific requirements of their research protocols.
How to dose Liraglutide (GLP1) 10mg?
The dosing of Liraglutide (GLP1) 10mg in vials form will vary according to the experiment being conducted. We do not provide dosage recommendations as our products are intended for research purposes only.
How to administer Liraglutide (GLP1) 10mg?
There are multiple methods of administering research products that are under investigation in various studies. The choice of administration technique should align with the specific goals and design of the researcher’s study. We provide products solely for research use, we do not offer advice on administration methods.
This is the extra content added to the product description.
You may also like…
by 
